Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al

Ann Rheum Dis. 2021 Feb;80(2):e20. doi: 10.1136/annrheumdis-2020-217636. Epub 2020 Apr 28.

Authors

Francesca Romana Spinelli¹, Fulvia Ceccarelli², Manuela Di Franco², Fabrizio Conti²

Affiliations

¹ Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Italy francescaromana.spinelli@uniroma1.it.
² Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Italy.

PMID: 32345618
DOI: 10.1136/annrheumdis-2020-217636

No abstract available

Keywords: autoimmune diseases; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

Antiviral Agents* / therapeutic use
COVID-19*
Chloroquine
Humans
Hydroxychloroquine / therapeutic use
SARS-CoV-2

Substances

Antiviral Agents
Hydroxychloroquine
Chloroquine